Drug Trial Radar · NCT02452190
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
Last checked: Nov 20, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
468
Actual
Start
Sep 28, 2015
Primary completion
Dec 4, 2017
Study completion Jan 31, 2018
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
- Sponsor type
- Industry
- Collaborators
- PPD Development, LP
- First posted
- May 22, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to determine the effect of reslizumab (110 mg) administered subcutaneously every 4 weeks on clinical asthma exacerbations in adults and adolescents with asthma and elevated blood eosinophils who are inadequately controlled on standard-of-care asthma therapy.
Conditions
- Asthma
Interventions
ReslizumabDrug
Reslizumab will be administered subcutaneously in a dose of 110 mg every 4 weeks.
PlaceboDrug
Matching Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Clinical Asthma Exacerbations (CAEs) During 52 Weeks of TreatmentTime frame: Day 1 to Week 52
Locations
226 sites in 21 countries. Site status is shown where the registry gives one.
Teva Investigational Site 13212
Birmingham, Alabama
Teva Investigational Site 13241
Flagstaff, Arizona
Teva Investigational Site 13194
Glendale, Arkansas
Teva Investigational Site 13215
Bakersfield, California
Teva Investigational Site 13181
Canoga Park, California
Teva Investigational Site 13254
Fresno, California
Teva Investigational Site 13216
Huntington Beach, California
Teva Investigational Site 13247
Long Beach, California
Teva Investigational Site 13205
Napa, California
Teva Investigational Site 13764
San Jose, California
Teva Investigational Site 13252
Stockton, California
Teva Investigational Site 13251
Walnut Creek, California
Teva Investigational Site 13229
Denver, Colorado
Teva Investigational Site 13766
Waterbury, Connecticut
Teva Investigational Site 13196
Aventura, Florida
Teva Investigational Site 13256
Fort Lauderdale, Florida
Teva Investigational Site 13203
Kissimmee, Florida
Teva Investigational Site 13197
Miami, Florida
Teva Investigational Site 13220
Miami, Florida
Teva Investigational Site 13243
Miami, Florida
Teva Investigational Site 13233
New Port Richey, Florida
Teva Investigational Site 13201
Orlando, Florida
Teva Investigational Site 13250
Orlando, Florida
Teva Investigational Site 13246
Pembroke Pines, Florida
Teva Investigational Site 13208
Tallahassee, Florida
Teva Investigational Site 13255
Tampa, Florida
Teva Investigational Site 13765
Albany, Georgia
Teva Investigational Site 13249
Buford, Georgia
Teva Investigational Site 13763
Lawrenceville, Georgia
Teva Investigational Site 13230
Chicago, Illinois
Teva Investigational Site 13211
Normal, Illinois
Teva Investigational Site 13235
Shiloh, Illinois
Teva Investigational Site 13202
Michigan City, Indiana
Teva Investigational Site 13225
Lenexa, Kansas
Teva Investigational Site 13222
Owensboro, Kentucky
Teva Investigational Site 13191
Lafayette, Louisiana
Teva Investigational Site 13200
North Dartmouth, Massachusetts
Teva Investigational Site 13226
Biloxi, Mississippi
Teva Investigational Site 13204
St Louis, Missouri
Teva Investigational Site 13258
Boys Town, Nebraska
Showing 40 of 226 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.